Frédéric Joël Desdouits
Chief Executive Officer at TreeFrog Therapeutics SAS
Frédéric Joël Desdouits active positions
Companies | Position | Start | End |
---|---|---|---|
Citoxlab France SAS
Citoxlab France SAS Miscellaneous Commercial ServicesCommercial Services Citoxlab France SAS operates as a research laboratory. It offers services in toxicology, genomics, pharmacology, pharmacokinetics, bio-analysis, ecotoxicology, stability testing and regulatory affairs. The company was founded in 1969 and is headquartered in Miserey, France. | Director/Board Member | - | - |
TreeFrog Therapeutics SAS
TreeFrog Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services TreeFrog Therapeutics SAS provides stem cell treatment services. It offers its expertise to patients of heart failure, diabetes, traumatic injury, skin burns, dermatitis, Huntington, and Parkinson disease. The company was founded by Maxime Feyeux, Kevin Alessandri, Jean-Luc Treillou, Erwan Bezard, Laurent Cognet, and Pierre Nassoy and is headquartered in Pessac, France. | Director/Board Member | 12/09/2021 | - |
Chief Executive Officer | 12/09/2021 | - | |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | Director/Board Member | - | - |
Career history of Frédéric Joël Desdouits
Former positions of Frédéric Joël Desdouits
Companies | Position | Start | End |
---|---|---|---|
CU CHEMIE UETIKON GmbH
CU CHEMIE UETIKON GmbH Chemicals: SpecialtyProcess Industries CU CHEMIE UETIKON GmbH engages in the production and development of active ingredients, pharmaceutical intermediates, as well as specialty chemicals for the chemical, pharmaceutical, and electronics industries. The company was founded on November 5, 1991 and is headquartered in Lahr, Germany. | Chief Executive Officer | 22/10/2017 | 24/06/2020 |
PCAS | Chief Executive Officer | 13/03/2019 | 22/03/2020 |
Corporate Officer/Principal | 28/02/2018 | 13/03/2019 | |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | Corporate Officer/Principal | 31/08/2011 | 31/08/2017 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Director/Board Member | 18/07/2010 | 31/08/2011 |
SANOFI | Corporate Officer/Principal | 31/08/2010 | 31/05/2011 |
Bionest Partners SAS
Bionest Partners SAS Miscellaneous Commercial ServicesCommercial Services Bionest Partners SAS operates as a global consulting firm which focuses on pharma, biotech, medical device and diagnostics. It offers strategy development, product planning and assessment services. The company was founded by Robert J. Easton and Alain J. Gilbert and is headquartered in Paris, France. | Corporate Officer/Principal | 31/12/2003 | 31/12/2010 |
░░░░░░░ ░░░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░ ░░░░░░░░ | ░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Training of Frédéric Joël Desdouits
Ecole Polytechnique | Undergraduate Degree |
College de France | Doctorate Degree |
The Rockefeller University | Doctorate Degree |
Statistics
International
France | 15 |
United States | 2 |
Germany | 2 |
Operational
Director/Board Member | 5 |
Corporate Officer/Principal | 5 |
Chief Executive Officer | 3 |
Sectoral
Health Technology | 6 |
Consumer Services | 5 |
Commercial Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
GENFIT | Health Technology |
SANOFI | Health Technology |
PCAS | Process Industries |
Private companies | 10 |
---|---|
Exane SA (Broker)
Exane SA (Broker) Investment Banks/BrokersFinance Exane SA (Broker) (Exane) is the brokerage division of Exane SA, itself a subsidiary of Verner Investissements SAS in France. Established in 2004 as a joint venture between BNP Paribas and Verner Investissements, the firm is based in Paris and specializes in European equity research and broking activities. Exane has research centers in Paris and London which are supported by a team of economists and strategists. | Finance |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Health Technology |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | Health Technology |
Université Pierre et Marie Curie | Consumer Services |
Bionest Partners SAS
Bionest Partners SAS Miscellaneous Commercial ServicesCommercial Services Bionest Partners SAS operates as a global consulting firm which focuses on pharma, biotech, medical device and diagnostics. It offers strategy development, product planning and assessment services. The company was founded by Robert J. Easton and Alain J. Gilbert and is headquartered in Paris, France. | Commercial Services |
Citoxlab France SAS
Citoxlab France SAS Miscellaneous Commercial ServicesCommercial Services Citoxlab France SAS operates as a research laboratory. It offers services in toxicology, genomics, pharmacology, pharmacokinetics, bio-analysis, ecotoxicology, stability testing and regulatory affairs. The company was founded in 1969 and is headquartered in Miserey, France. | Commercial Services |
Bionest Partners Finance SAS | |
CU CHEMIE UETIKON GmbH
CU CHEMIE UETIKON GmbH Chemicals: SpecialtyProcess Industries CU CHEMIE UETIKON GmbH engages in the production and development of active ingredients, pharmaceutical intermediates, as well as specialty chemicals for the chemical, pharmaceutical, and electronics industries. The company was founded on November 5, 1991 and is headquartered in Lahr, Germany. | Process Industries |
TreeFrog Therapeutics SAS
TreeFrog Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services TreeFrog Therapeutics SAS provides stem cell treatment services. It offers its expertise to patients of heart failure, diabetes, traumatic injury, skin burns, dermatitis, Huntington, and Parkinson disease. The company was founded by Maxime Feyeux, Kevin Alessandri, Jean-Luc Treillou, Erwan Bezard, Laurent Cognet, and Pierre Nassoy and is headquartered in Pessac, France. | Commercial Services |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | Health Technology |